Kyverna Therapeutics Inc (NASDAQ: KYTX) on Monday, soared 6.81% from the previous trading day, before settling in for the closing price of $4.55. Within the past 52 weeks, KYTX’s price has moved between $3.92 and $35.06.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -37.90% over the past five years. The company achieved an average annual earnings per share of 96.32%. With a float of $18.70 million, this company’s outstanding shares have now reached $43.17 million.
Let’s look at the performance matrix of the company that is accounted for 96 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Kyverna Therapeutics Inc (KYTX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Kyverna Therapeutics Inc is 56.68%, while institutional ownership is 31.26%. The most recent insider transaction that took place on Feb 12 ’24, was worth 5,568,992. In this transaction 10% Owner of this company bought 253,136 shares at a rate of $22.00, taking the stock ownership to the 252,553 shares. Before that another transaction happened on Feb 12 ’24, when Company’s 10% Owner bought 450,000 for $22.00, making the entire transaction worth $9,900,000. This insider now owns 3,163,868 shares in total.
Kyverna Therapeutics Inc (KYTX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 96.32% per share during the next fiscal year.
Kyverna Therapeutics Inc (NASDAQ: KYTX) Trading Performance Indicators
Kyverna Therapeutics Inc (KYTX) is currently performing well based on its current performance indicators. A quick ratio of 10.50 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.07, a number that is poised to hit -0.84 in the next quarter and is forecasted to reach -3.69 in one year’s time.
Technical Analysis of Kyverna Therapeutics Inc (KYTX)
Kyverna Therapeutics Inc (NASDAQ: KYTX) saw its 5-day average volume 0.46 million, a positive change from its year-to-date volume of 0.46 million. As of the previous 9 days, the stock’s Stochastic %D was 12.96%. Additionally, its Average True Range was 0.57.
During the past 100 days, Kyverna Therapeutics Inc’s (KYTX) raw stochastic average was set at 13.72%, which indicates a significant decrease from 28.66% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 142.13% in the past 14 days, which was higher than the 88.13% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.00, while its 200-day Moving Average is $11.79. Nevertheless, the first resistance level for the watch stands at $5.20 in the near term. At $5.54, the stock is likely to face the second major resistance level. The third major resistance level sits at $5.85. If the price goes on to break the first support level at $4.55, it is likely to go to the next support level at $4.23. Assuming the price breaks the second support level, the third support level stands at $3.89.
Kyverna Therapeutics Inc (NASDAQ: KYTX) Key Stats
Market capitalization of the company is 205.30 million based on 43,172K outstanding shares. Right now, sales total 0 K and income totals -60,370 K. The company made 0 K in profit during its latest quarter, and -34,490 K in sales during its previous quarter.
